MktsMarkets

Teva Pharmaceutical Industries Limited
NYSE: TEVAKey statistics
TEVA News
Stories mentioning TEVA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 3,982,000 | 1,500,000 | 4,480,000 | 4,176,000 | 3,891,000 | 4,229,000 | 4,332,000 | 4,164,000 |
| Cost of Goods Sold | 2,011,000 | 2,056,000 | 2,176,000 | 2,074,000 | 2,014,000 | 2,110,000 | 2,183,000 | 2,140,000 |
| Gross Profit | 1,972,000 | 2,655,000 | 2,304,000 | 2,102,000 | 1,877,000 | 2,121,000 | 2,148,000 | 2,024,000 |
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 652,000 | 301,000 | 882,000 | 455,000 | 519,000 | (29,000) | (51,000) | (5,000) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 67,000 | (390,000) | 214,000 | (78,000) | 74,000 | 29,000 | 69,000 | 630,000 |
| Net Income (Loss) | 369,000 | 481,000 | 433,000 | 282,000 | 214,000 | (217,000) | (437,000) | (846,000) |
| Earnings Per Share (Basic) | 0.32 | 0.42 | 0.38 | 0.25 | 0.19 | (0.19) | (0.39) | (0.75) |
| Earnings Per Share (Diluted) | 0.31 | 0.41 | 0.37 | 0.24 | 0.18 | (0.19) | (0.39) | (0.75) |
| Weighted Average Shares Outstanding (Basic) | 1,156,000 | 1,145,000 | 1,147,000 | 1,147,000 | 1,138,000 | 1,131,000 | 1,133,000 | 1,133,000 |
| Weighted Average Shares Outstanding (Diluted) | 1,179,000 | 1,163,000 | 1,164,000 | 1,161,000 | 1,159,000 | 1,131,000 | 1,133,000 | 1,133,000 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TEVA
Teva Pharmaceutical Industries Limited (NYSE: TEVA) is a stock listed on the New York Stock Exchange under the ticker symbol TEVA. It last traded at $42.09 (Oct 30, 2026, 4:00 PM ET), up 1.5% on the day. That gives Teva Pharmaceutical Industries a market capitalisation of $148.2B and a price-to-earnings ratio of 67.0.
Over the past 52 weeks TEVA has traded between $6,207.00 and $13,070.00.
Revenue for the quarter ended Mar 31, 2026 was $4.0B; net income $369.0M. Revenue was up 2.3% from $3.9B in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $4.0B | $369.0M | 9.3% |
| Dec 31, 2025 | $1.5B | $481.0M | 32.1% |
| Sep 30, 2025 | $4.5B | $433.0M | 9.7% |
| Jun 30, 2025 | $4.2B | $282.0M | 6.8% |
From Teva Pharmaceutical Industries’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…